Abstract
Programmed cell death (pcd) is a form of cell death in which the cell plays an active role in its own demise. Pcd plays a critical role in the development of the nervous system, as well as in its response to insult. Both anti-pcd and pro-pcd modulators play prominent roles in development and disease, including neurodegeneration, cancer, and ischemic vascular disease, among others. Over 100,000 published studies on one form of programmed cell death — apoptosis — have appeared, but recent studies from multiple laboratories suggest the existence of non-apoptotic forms of programmed cell death, such as autophagic programmed cell death. In addition, there appear to be programmatic cell deaths that do not fit the criteria for either apoptosis or autophagic cell death, arguing that additional programs may also be available to cells. Constructing a mechanistic taxonomy of all forms of pcd — based on inhibitors, activators, and identified biochemical pathways involved in each form of pcd — should offer new insight into cell deaths associated with various disease states, and ultimately offer new therapeutic approaches.
Keywords: Programmed cell death, autophagy, caspase, apoptosis, paraptosis, dependence receptors, neurodegeneration, Alzheimer's disease
Current Molecular Medicine
Title: Programmed Cell Death Mechanisms in Neurological Disease
Volume: 8 Issue: 3
Author(s): Dale E. Bredesen
Affiliation:
Keywords: Programmed cell death, autophagy, caspase, apoptosis, paraptosis, dependence receptors, neurodegeneration, Alzheimer's disease
Abstract: Programmed cell death (pcd) is a form of cell death in which the cell plays an active role in its own demise. Pcd plays a critical role in the development of the nervous system, as well as in its response to insult. Both anti-pcd and pro-pcd modulators play prominent roles in development and disease, including neurodegeneration, cancer, and ischemic vascular disease, among others. Over 100,000 published studies on one form of programmed cell death — apoptosis — have appeared, but recent studies from multiple laboratories suggest the existence of non-apoptotic forms of programmed cell death, such as autophagic programmed cell death. In addition, there appear to be programmatic cell deaths that do not fit the criteria for either apoptosis or autophagic cell death, arguing that additional programs may also be available to cells. Constructing a mechanistic taxonomy of all forms of pcd — based on inhibitors, activators, and identified biochemical pathways involved in each form of pcd — should offer new insight into cell deaths associated with various disease states, and ultimately offer new therapeutic approaches.
Export Options
About this article
Cite this article as:
Bredesen E. Dale, Programmed Cell Death Mechanisms in Neurological Disease, Current Molecular Medicine 2008; 8 (3) . https://dx.doi.org/10.2174/156652408784221315
DOI https://dx.doi.org/10.2174/156652408784221315 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IAPs, their Antagonists and their Role in Neurological Disease and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Polyglutamine and Neurodegeneration: Structural Aspects
Protein & Peptide Letters Melatonin and Its Therapeutic Potential in Neuroprotection
Central Nervous System Agents in Medicinal Chemistry A Review on Synthesis of Benzothiazole Derivatives
Current Organocatalysis Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Biochemical and Therapeutic Effects of Antioxidants in the Treatment of Alzheimers Disease, Parkinsons Disease, and Amyotrophic Lateral Sclerosis
Current Drug Targets - CNS & Neurological Disorders Targeting Oxidative Stress Component in the Therapeutics of Epilepsy
Current Topics in Medicinal Chemistry Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?
CNS & Neurological Disorders - Drug Targets Dental Stem Cell Patents
Recent Patents on DNA & Gene Sequences Editorial [Hot topic: Endocannabinoid Signaling and Neuroinflammatory Diseases (Executive Editor: Mauro Maccarrone)]
Current Pharmaceutical Design Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Under the Microscope: Focus on Chlamydia pneumoniae Infection and Multiple Sclerosis
Current Neurovascular Research Editorial [Hot Topic: Advances in Alzheimer Therapy: Development of Innovative New Strategies (Guest Editors: Nigel H. Greig, Ezio Giacobini and Debomoy K. Lahiri)]
Current Alzheimer Research Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Human Tooth Germ Stem Cells Preserve Neuro-Protective Effects after Long-Term Cryo-Preservation
Current Neurovascular Research Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry